Findings
The clinical research ecosystem has longstanding diversity gaps, making targeted DEI strategies essential for equitable healthcare innovation.
Digital tools, including virtual visits, digital outreach campaigns, and AI-driven analytics, can increase access to trials for underrepresented populations.
Real-world data (RWD) and real-world evidence (RWE) help identify diverse participant pools and optimize recruitment strategies.
eConsent and educational resources improve patient engagement and retention by making clinical trials more transparent and accessible.
Trust-building measures, such as community partnerships and patient advocacy collaborations, are critical for long-term success in diversifying clinical trials.

Recommendations
Clinical trial sponsors should integrate digital tools at each stage of trial design to enhance participant diversity and reduce barriers to participation.
AI/ML and real-world data should be leveraged to identify, recruit, and retain diverse patient populations in a data-driven manner.
Digital engagement strategies, including social media outreach and mobile-friendly platforms, should be employed to improve awareness and accessibility.
Transparent communication, including clear eConsent processes and on-demand educational materials, should be prioritized to foster participant trust.
A comprehensive tracking system should be implemented to measure progress on diversity goals, ensuring accountability in clinical trial execution.

Regulatory Considerations
The FDA Diversity Plan requirement should be incorporated into clinical trial planning, with measurable targets for diverse participant inclusion.
Digital tools used for recruitment and engagement must comply with HIPAA, GDPR, and other privacy regulations to protect participant data.
The use of real-world evidence (RWE) in regulatory submissions should be expanded to demonstrate the efficacy of digital recruitment and retention strategies.
Standardized DEI reporting frameworks should be established to ensure regulatory bodies can assess the impact of diversity initiatives in clinical research.
Clinical trials utilizing digital tools should align with decentralized clinical trial (DCT) regulatory guidance to maximize accessibility and equity.